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Objective. With this review, we provide a comprehensive overview of the main aspects and currently used drugs for analgesia
in shockwave lithotripsy. Evidence Acquisition. We reviewed current literature, concentrating on newer articles and high-quality
reviews in international journals. Results. No standardized protocols for pain control in SWL exist, although it is crucial for
treatment outcome. General and spinal anaesthesia show excellent pain control but are only recommended for selected cases.
The newer opioids and nonsteroidal anti-inﬂammatory drugs are able to deliver good analgesia. Interest in inhalation anaesthesia
with nitrous oxide, local anaesthesia with deep inﬁltration of the tissue, and dermal anaesthesia with EMLA or DMSO has recently
rekindled, showing good results in terms of pain control and a favourable side eﬀect proﬁle. Tamsulosin and paracetamol are
further well-known drugs being currently investigated. Conclusion. Apart from classically used drugs like opioids and NSARs,
medicaments like nitrous oxide, paracetamol, DMSA, or reﬁned administration techniques for inﬁltration anaesthesia show a
good eﬀectiveness in pain control for SWL.
1.Introduction
With the ﬁrst serial lithotripter, the Dornier HM3 (Human
Model 3), introduced in 1983 by Chaussy et al., treatment
waspainfuland thereforetheprocedurehadto beperformed
under general or spinal anaesthesia [1].
The subsequent generations of shock wave lithotripsy
(SWL) machines were optimized towards patient comfort
and treatments became less painful. Modiﬁcation of the
shockwavegeneratorstowardsawiderapertureledtoaredu-
ced intensity of the shock waves on skin entry level, a smaller
focal zone and a lower energy output made the treatment
under analgesia rather than under anaesthesia possible [1].
But, also with a second-generation machine, the Dornier
HM4, still 95% of SWL patients experienced pain during
the treatment [2]. Especially the piezoelectric lithotripters
are an example for a very wide area of entry over the skin
with a very small focal point. Treatment with these machines
was hoped to become pain-free [3]; nevertheless, even with
the modiﬁed and adapted third generation machines, nearly
30% of all patients still reported severe pain when treated
without analgesia [3].
Clinical outcomes and success as measured in terms of
stone-free rate after SWL is strongly correlated to pain expe-
rienced during treatment [4]. Pain during SWL treatment
may lead to defocussing through voluntary or involuntary
patient movement and can cause increased respiratory
motion, both resulting in a reduced hit rate with a reduced
stone fragmentation and a lower overall stone clearance.
Additionally, pain which reduces the patient’s compliance,
can limit the shockwave energy and number and may lead to
more complications like a higher rate of kidney haematomas
due to a rise in blood pressure. It is evident that despite lat-
est generation machines, SWL is still a painful procedure
and adequate analgesia is mandatory in order to achieve an
optimal result and patient compliance [5].
The optimal anaesthesia technique should be easy to
administer and have a high eﬃcacy and minimal side eﬀects.
Adequate analgesia, suﬃcient sedation, and rapid recovery
are needed, the latter especially in an outpatient setting. To
achieve optimal pain control, the patient needs to be closely
monitored regarding this during the treatment, ideally by
the operator who is controlling the applied energy level and
can immediately reduce it, should pain occur. For protocols,2 Pain Research and Treatment
where opioids or sedatives are administered, a second person
other than the operator needs to be present to monitor the
patient’s vital functions and to deliver drugs according to the
p a t i e n t ’ sn e e d s[ 6, 7].
To date, there are no guidelines for pain therapy during
SWL treatment and a variety of treatment protocols and
drugs are being used. Traditionally, nonsteroidal, anti-
inﬂammatory drugs (NSAIDs) such as diclofenac, ketorolac
and piroxicam, as well as a variety of opioids like morphine,
pethidine, and fentanyl are employed sometimes in combi-
nation with sedative hypnotics.
In this review, we emphasize newer drugs and drugs in
which interest has been rekindled recently such as inhalation
anaesthesia with nitrous oxide, local inﬁltration techniques,
topical creams, newer opioids, and NSAIDs.
2. Pathogenesis of Pain duringSWL
Shock-wave-induced pain is usually described as stinging
and sharp. Its pathogenesis is not yet totally understood but
cavitation seems to play a key role, rather than direct mecha-
nical eﬀects on nociceptive nerve endings [8, 9]. Formation,
movement, and implosion of the shock wave generated
microbubbles in body ﬂuids or tissues lead to stimulation of
the superﬁcial nociceptors in the skin as well as the deeper,
visceral nociceptors in the renal capsule, periost, pleura,
peritoneum, and muscles [9, 10].
A second component of shock-wave-related pain is the
movement of the stone caused by the impact of the shock
wave [11].
Several physical variables inﬂuencing treatment-related
pain have been identiﬁed: an important role is played by
the type of the shockwave source, size, and site of stone
burden (e.g., upper-pole stone near the ribs), peak pressure
of the shockwaves, diameter of the focal zone, and size of
the aperture of the shockwave source reﬂecting the area of
shockwave entry at the skin [12–14].
Furthermore responsible for pain perception during
SWL are patient-related factors like age, gender, and body
habitus [4], and young female patients, anxious and dep-
ressed patients or thin patients (shockwaves more concen-
trated) all experience more pain during SWL [15, 16].
3. Contemporary Drugs:Characteristicsand
Side Effects
3.1. General Anaesthesia (GA). General anaesthesia (GA) for
SWL treatment oﬀers optimized pain control and controlled
respiratory excursion. This creates optimal conditions for
stone targeting and consecutive fragmentation. In modern
anaesthetic practice, GA is considered to be safe with a
low morbidity. However, it seems preferable to avoid, if not
mandatory, especially in high-risk patients. Disadvantages
are the need to involve an anaesthetic specialist and the need
for postoperative recovery, increasing the overall costs and
making GA less suitable in the common outpatient SWL
setup of most urological departments. Solely in children or
in extremely anxious patients, it is still the preferred option.
Other potential indications are particularly long treat-
ments as in patients with bilateral stones, concomitant renal
and ureteral stones or in patients with very hard calculi
(cystine, calcium oxalate monohydrate, or brushite), which
are known to be resistant to fragmentation and require high,
potentially painful energy levels [14, 17].
3.2. Inhalation Anaesthesia with Nitrous Oxide. Nitrous oxide
is a medical anesthetic gas and on the market as Entonox,
a mixture of 50% nitrous oxide and 50% oxygen. It was
discovered in 1776 by Joseph Priestly [18] and constitutes
another analgesic option for SWL treatment.
Thiscolourlessgasishighlysolubleinbloodandthearte-
rial concentration reaches a plateau 10 minutes after com-
mencing the inhalation. It diﬀuses rapidly through the cellu-
lar membranes, does no bind to haemoglobin, and is elim-
inated unchanged via the lungs. The analgesic eﬀect com-
mences 20 to 30 seconds after inhalation and a peak eﬀect
is reached after 3 to 5 minutes. Reﬂexes of coughing and
airway protection are not noticeable altered [18]. This rapid
onsetandquicklossofeﬀectmakenitrousoxideanattractive
option for day-case procedures. Especially in treatments of
short duration such as SWL, Entonox can be used in spon-
taneously breathing patients to provide analgesia. Regarding
its analgesic eﬀect, the concentration of 30% of nitrous oxide
is reported to be equivalent to 10–15mg of morphine [19].
Adverse eﬀects of Entonox are mainly transient nausea
and light headedness. A further issue can be slight cardiac
depression; therefore, the gas should be used carefully in
patients with congestive heart failure and in those with obst-
ructive airway disease [20]. It is contraindicated in patients
with pathological air-ﬁlled body cavities (pneumothorax or
obstructed bowels) as nitrous oxide is diﬀusing into these,
consecutively increasing volume and pressure therein.
TheuseofEntonoxduringSWLwasreportedinonlyone
RCT study up to now; 150 patients undergoing treatment
where randomized into 3 groups, one to receive Entonox,
the other to have intravenous pethidine, and the last one to
inhale compressed air. A signiﬁcantly reduced procedure-
relatedpain(P =0.001)fornitrousoxidecouldbeshownand
it proved as eﬀective as intravenous administered pethidine
[21].
3.3. Spinal Anaesthesia. Spinal anaesthesia with subarach-
noidally injected local anaesthetics or opioids has shown
excellent results in terms of analgesia which makes it suitable
for a variety of surgical procedures. Its use for SWL with
application of lidocaine and sufentanil has been repeatedly
described and again the results in terms of analgesic eﬀect
are excellent [22–25].
Sufentanilisconsideredtobethesaferalternativetolido-
caine as it preserves motor and sensory function, facilitating
earlier ambulation and discharge [14, 24]. An undesirable
side eﬀect of sufentanil is pruritus, and inconvenient for the
urologist is the need for active patient monitoring [22, 25]
and due to the risk of respiratory depression it should be
used with caution, especially in the elderly or in patients
with obstructive airway disease [3]. Furthermore, spinal
anaesthesiaitisatime-consumingprocedure;ananaesthetist
must be involved and patients have a prolonged recovery
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3.4. Inﬁltrating Local Anaesthesia. The analgesic eﬃcacy of
subcutaneous (SC) inﬁltration of lidocaine with 1:100.000
epinephrine for SWL has early been demonstrated. However,
inﬁltrating a relatively large area (200cm2) with signiﬁcant
discomfort at the site of injection and the need for additional
IV analgesia and sedation made this approach inconvenient
[3, 26].
Prilocaine has an equal analgesic eﬃcacy, a more rapid
onset, a similar duration, and is due to its rapid metabolism,
less toxic. The target area is usually inﬁltrated only 1-2min
before the treatment. Yilmaz et al. inﬁltrated a limited area
of30cm2 representingtheentryareaoftheshockwaveonthe
skin with prilocaine. Compared to intra-muscularly admin-
istered diclofenac, less supplementary analgesia (fentanyl)
was needed [27]. By inﬁltrating 20mL prilocaine subcuta-
neously and deep lumbar, an even better analgesic eﬀect
could be shown, thus minimizing the need for additional
analgesia [28]. Recently, the combination of subcutaneous
inﬁltration of 10mL 2% lidocaine and 10mL 0.5% bupiva-
caine, administered 5min before the treatment has shown
to be suﬃciently analgesic during SWL treatment and only
rarely additional intravenous analgesia was needed [29].
3.5. Dermal Anaesthesia. EMLA (Eutectic Mixture of Local
Anaesthetics) cream is an eutectic mixture of lidocaine 2.5%
and prilocaine 2.5% for topical application. It is commonly
used for dermal anaesthesia, for example, in blood sampling,
venous catheterization, condylomata acuminata excision, or
debridement of leg ulcers. Its penetration depth through
intact skin is about 4mm after 60 minutes [30, 31]. Its use
in SWL for pain relief has early been reported [32].
To maximize its local analgesic eﬀect, EMLA should
be applied under an occlusive dressing. Due to its com-
parable weak analgesic potential, it is usually used in
SWL together with additional analgesic agents like opioids
or NSAIDs [13]. The ultrasound-jelly-like viscosity is a
favourable characteristic since it acts as a coupling medium
[17]. A further advantage of this form of analgesia is its
simplicity and noninvasiveness, avoiding the side eﬀects
of IM or IV analgesic agents. To achieve a maximal
analgesic eﬀect, the cream needs to be applied 60 to 90
minutes before the procedure, application is not partic-
ularly time consuming but a good timing is crucial [33,
34].
Whilst earlier studies showed no reduction in the need
for additional opioid analgesics after application of EMLA
cream [35], a more recent randomized study comparing
oral Diclofenac, EMLA cream, and a combination of both
reported a favourable outcome. There was no need for
additional parenteral analgesics in the latter group, and as a
result a better overall stone-free rate and reduced procedure
related complications could be shown [36].
Dimethyl sulfoxide (DMSO) acts as a topical analgesic
and is at the same time a vehicle for the transport of
other local acting pharmaceuticals through the skin [36]. In
addition, ithasanti-inﬂammatory, musclerelaxing,hydroxyl
radical scavenger, and diuretic eﬀects [37]. In combination
with lidocaine, it has shown to deliver a better pain control
compared to EMLA cream [38].
3.6. Opioids. Frequently used drugs are pethidine, the ﬁrst
synthetic opioid, fentanyl, tramadol, alfentanil, remifentanil,
and sufentanil and a variety of administration techniques
such as intramuscular bolus (IM) injection, or intravenous
(IV) on-demand patient-controlled analgesia [11, 36].
Opioids are delivered either alone or in combination
with other forms of analgesia or sedation [39–41]. Due to
sideeﬀectslikenausea,vomiting,andrespiratorydepression,
opioids require ECG, blood pressure and oxygen satura-
tion monitoring which limits their use, especially in an
outpatient setting [42, 43]. The combination of opioids
and benzodiazepines has shown to decrease the need for
IV opioid analgesia and led to high patient satisfaction
[44].
Fentanyl is a potent synthetic narcotic, has a rapid onset
and a short duration of action. It is a strong agonist at
the μ-opioid receptors, provides an acceptable analgesia
condition during SWL, and is therefore commonly used.
One of its drawbacks is the need for continuous noninvasive
pulseoximetryduetoitsmarkedrespiratorydepressiveeﬀect
[45]. The combination of fentanyl and propofol has shown
to be even more potent analgesic in SWL at the costs of
more pronounced side eﬀects like respiratory depression,
decreasing oxygen saturation, nausea, vomiting, drowsiness,
and hypersensitivity reactions [40, 46]. Remifentanil and
sufentanil are more recent developments and have been
used in SWL alone or in combination with sedatives, local
anaesthetics, or other analgesics [42, 47–49]. They are
equal in their analgesic potency and have shown to lead
to similar patient’s and surgeon’s satisfaction. Remifentanil
has the more convenient side eﬀect proﬁle leading to lesser
respiratory depression, nausea, and vomiting [42]. Both of
them can safely be applied in patients with hepatic or renal
diseases [49].
Tramadol hydrochloride is a relatively weak, central
active opioid analgesic, acting as an agonist at the μ-opioid
receptors, inhibiting the reuptake of noradrenalin and rele-
asing 5-hydroxytryptamine (Serotonin) [50]. Respiratory
depression is not clinically signiﬁcant in normal doses [51].
For a dose of 100mg of tramadol IV, eﬃcient pain control
during SWL has been reported, despite relatively higher
rate of side eﬀects, especially a high incidence (25%) of
nausea and vomiting [49, 52]. The mechanism triggering
nausea and vomiting remains unclear but seems to
be related to its central eﬀect on opioid receptors
[45].
Patient-controlled analgesia avoids problems of IV opi-
oid overadministration such as respiratory depression and
the need for intra- and postoperative patient monitoring
[53]. Every time the patient presses a button, a small
predeﬁned dose is delivered and a safety mechanism does
not release another dose before a set time. Theoretically,
t h i so p t i o np r o v i d e sm o r ep a i nc o n t r o la n dm o r ee ﬀective
targeting should be possible [54]. Nevertheless it requires an
active intelligent patient, the device is expensive and prob-
lems of malfunctioning can occur. Furthermore, patients
need to be actively monitored and continuous noninvasive
pulse oximetry is mandatory during and up to 2 hours after
administration [11, 45].4 Pain Research and Treatment
Staﬀ administering the above listed substances should be
trained in cardiopulmonary resuscitation and the appropri-
ate reversal agents should be at hand: naloxone for opioid
reversal and ﬂumazenil for benzodiazepine reversal [17].
3.7. Nonsteroidal Antiinﬂammatory Drugs (NSAIDs). Diclo-
fenac, ketorolac, and piroxicam are widely used for SWL as
they have a good analgesic eﬀect [4, 17, 36]. By inhibiting the
enzymecyclooxygenase(COX),NSAIDsreducethesynthesis
of prostaglandins, which act as messengers in inﬂammatory
processes; they reduce the renal blood ﬂow, the renin release,
and the glomerular ﬁltration rate. On the other hand, by
blocking the synthesis of thromboxane, they also have an
antithrombotic eﬀect and aﬀect haemostasis, potentially
leadingtoaprolongedbleedingtime[4].Todistinguishthem
from steroids, which have (amongst many others) a similar
prostaglandin depressing, antiinﬂammatory action, the term
“nonsteroidal” is used. In contrast to many other analgesic
drugs, NSAIDs are nonnarcotic.
They can be given orally, intravenously, intramuscularly,
or rectally [11, 27, 36]. They are not indicated in patients
with a history of intestinal ulcers, renal and hepatic insuf-
ﬁciency, chronic obstructive pulmonary disease (COPD),
and coagulation disorders allergies [14]. Depending on the
way of administration, they should be given 30 to 60 minu-
t e sb e f o r et h ep r o c e d u r e[ 36]. Side eﬀects include gastroin-
testinal disturbances, hypersensitivity reactions, and coagu-
lation disorders due to cyclooxygenase inhibition [55].
Lornoxicam is a short-acting, nonsteroidal anti-inﬂam-
matory agent, inhibiting COX-1 and COX-2 and belonging
to the oxicam group [56]. A single dose of 8mg lornoxicam
has proved to be eﬀective for pain relief during SWL, being
superior 20mg of tenoxicam, which is another drug of the
same class [44, 57].
Selective cyclooxygenase-2-inhibitors (COX-2) are par-
ticularly interesting for pain relief during or after surgical
procedures such as SWL, as they have no eﬀect on throm-
boxane and a potential better side eﬀect proﬁle. They are not
yet widely in use for pain relief during SWL, only parecoxib,
which can be administered IV or IM has recently been under
investigation, showing a rather limited analgesic eﬀect and
proving to be remarkably less eﬀective than fentanyl [58].
Rofecoxib is another COX-2 inhibitor, which showed
to provide good pain relief after SWL treatment, but in
the meantime this substance has been withdrawn from the
market due to safety concerns [59].
3.8. Paracetamol. Paracetamol is a derivative of p-amino-
phenol. It is not counted to the NSAIDs because it has
no anti-inﬂammatory eﬀect. It is commonly used for pain
control after surgical procedures.
There is only one study in the literature proving the
eﬃcacy of paracetamol in SWL [60].
3.9. Tamsulosin. Tamsulosin is an α1a-selective alpha blocker
and widely used in urology for the symptomatic treatment
of urinary outﬂow obstruction due to benign prostate
enlargement. It has also been shown to increase stone-free
rate after SWL treatment and to reduce the need for opioid
analgesics in patients with renal colics [61]. It was currently
under investigation for pain relief during SWL treatment but
up to now, no signiﬁcant beneﬁt could be shown [62].
3.10. Multimodal Analgesia. Multimodal (or balanced) anal-
gesia represents a modern approach to pain control during
surgery by administering a combination of opioid and
nonopioid analgesics like local anesthetics, NSAIDs, COX-2
inhibitors, acetaminophen, ketamine, dextromethorphan, α-
2 agonists, gabapentin, magnesium, and neostigmine [63].
These nonopioid analgesics are increasingly being used as
adjuvants before, during, and after surgery to reduce the
amount of administered opioids and to facilitate thereby
the recovery process. Such an approach is already common
practice for pain control during SWL treatment, where in
many cases a nonopioid like EMLA [13], subcutaneous
local anaesthetic [27] or NSAIDs [56] is administered
beforehand and supplementary analgesic needs are covered
with intravenous administered opioids.
4. Summary
Even with latest generation lithotripters, SWL is still a poten-
tial painful procedure and suﬃcient analgesia is mandatory
for good treatment results.
General anaesthesia should be reserved for selected cases
and for the treatment of children; the same applies to spinal
anaesthesia. Both guaranty optimal pain control but have
high demands of manpower, resources, and a lead to pro-
longed recovery, making them less suitable for SWL as an
outpatient procedure.
In this context, inhalational anaesthesia with nitrous
oxide is another, very interesting option, as it delivers good
analgesia, is easy to administer, and does not lead to pro-
longed recovery.
Subcutaneousinﬁltrationwithlocalanaestheticshaspro-
ven to be eﬀective in terms of pain control and safe, as it
avoids side eﬀects of opioids.
Theconceptofdermalanaesthesiaisnotnewbutremains
an interesting option due to the simplicity of its use and the
convenience for the patient. Especially the combination of
lidocaine with DMSO lately showed promising results.
Opioids, sometimes in combination with sedatives are
the classical substances for pain control in SWL. They have a
very good analgesic action, but also inconvenient side eﬀects,
require patient monitoring and lead to a delayed patient
discharge. Sedoanalgesia and patient-controlled analgesia
lead to good pain relief and patient satisfaction but are costly
and likewise limited in an outpatient setting.
NSAIDs are very convenient for both surgeon and pati-
ent.Theyareeasytoadminister,donotrequirepatientmoni-
toring and patients can be discharged immediately after the
procedure. The newer substance lornoxicam has proven to
have a good analgesic eﬀect, whereas selective cyclooxyge-
nase-2-inhibitors have not yet proven to be equally eﬀective.
Substances like Paracetamol and Tamsulosin are widely
in use for other indications and have recently been in the
focus. Their very convenient side eﬀect proﬁle makes them
very interesting, though the analgesic component, especially
of Tamsulosin, is not convincing.Pain Research and Treatment 5
Despite its crucial importance for the outcome, no stan-
dardized protocols for pain control in SWL exist. Whatever
substances or ways of administration are used, it remains
the duty of the operator to ensure a pain-free treatment, for
example, by delivering additional opioids on demand.
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